Trials / Completed
CompletedNCT02624375
Immune Response to Shingles Vaccination
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- University of Washington · Academic / Other
- Sex
- All
- Age
- 70 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to learn more about the immune response to varicella zoster virus (VZV).
Detailed description
Participants 70 years of age or older will receive the FDA-approved shingles vaccine (Zostavax). Blood samples and optional skin biopsies will be obtained before and after vaccination to study the immune responses to shingles vaccination.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zoster Vaccine Live |
Timeline
- Start date
- 2016-02-01
- Primary completion
- 2019-11-01
- Completion
- 2019-11-01
- First posted
- 2015-12-08
- Last updated
- 2019-12-05
- Results posted
- 2019-12-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02624375. Inclusion in this directory is not an endorsement.